NVDA
NVIDIA
-- 105.255 TSLA
Tesla
-- 249.820 PLTR
Palantir
-- 81.950 AMZN
Amazon
-- 185.880 GOOG
Alphabet-C
-- 153.242 
Why Summit Therapeutics Skyrocketed 123% This Week
$Summit Therapeutics (SMMT.US)$ surged 123.4% this week after its lung cancer drug Ivonescimab outperformed Keytruda in a phase 3 clinical trial. The trial, conducted with its partner Akeso in China, showed superior progression-free survival for patients with PD-L1 gene expression.
Analysts raised price targets for Summit, speculating that Ivonescimab could challenge Keytruda in the $50 billion lung cancer drug market. Summit also raised $235 million from biotech investors through a stock offering, boosting investor confidence further.
With over 1,000% growth this year, Summit is now a biotech stock to watch, though future revenue and profit impact remains uncertain.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment